Eli Lilly’s Peptide Power Grab: When Patent Protection Becomes Market Control
America’s payment networks should not be used as private enforcement arms for powerful pharmaceutical corporations.
Eli Lilly owns important patents covering tirzepatide, the active ingredient in Mounjaro and Zepbound. The company has the legal right to defend those specific patents through the courts. However, owning patents associated with tirzepatide does not mean Lilly owns the entire peptide industry—and it should not give the pharmaceutical giant the power to financially blacklist every business operating within that market.
Unfortunately, peptide businesses, payment processors, and acquiring banks are now feeling the consequences of an enforcement campaign that reaches far beyond an ordinary patent dispute.
Lilly Is Aggressively Targeting the Market
Lilly has sent cease-and-desist letters and filed lawsuits against compounding pharmacies, telehealth companies, wellness clinics, medical providers, and businesses associated with compounded tirzepatide.
The company has raised allegations involving patent infringement, trademark violations, false advertising, unapproved drugs, patient safety, and improper compounding practices. Lilly has also warned consumers against compounded and alternative versions of tirzepatide.
Some of these concerns deserve legitimate investigation. Counterfeit products, contaminated medications, deceptive advertising, and businesses falsely claiming FDA approval should be taken seriously.
However, enforcement must be precise and supported by evidence. It cannot become an excuse to eliminate competition, restrict lawful commerce, or treat every peptide company as though it were selling counterfeit Mounjaro.
Lilly Does Not Own “Peptides”
Peptides are an enormous and diverse category of compounds. Tirzepatide is one particular peptide-based medication.
Lilly’s patent rights do not automatically extend to semaglutide, BPC-157, CJC-1295, ipamorelin, tesamorelin, or every other product described as a peptide. Each compound, product, merchant, and business model must be evaluated on its own facts.
Even within the tirzepatide market, questions involving patent rights, pharmacy compounding, individualized prescriptions, FDA regulations, trademarks, and medical necessity can be complicated legal matters.
Those questions should be decided through proper regulatory and judicial processes—not through quiet pressure placed on banks and payment processors.
A multinational pharmaceutical company should not be able to say, in effect, “We own patents involving one compound, so shut down payment processing for an entire industry.”
Visa Is Fining Processors That Approve Peptide Merchants
This is no longer simply a matter of peptide businesses having difficulty finding payment processing. Visa is imposing fines on processors and acquiring institutions that approve or maintain peptide merchants.
Those penalties create enormous pressure throughout the payment chain. Even when a peptide company believes it is operating lawfully, its processor may decline or terminate the account rather than risk fines, monitoring-program assessments, increased oversight, or damage to its relationship with Visa.
The result is a de facto financial blockade.
Lilly does not have to win a patent-infringement lawsuit against every peptide merchant individually if the payment system makes it practically impossible for those businesses to accept cards. Once Visa threatens processors with financial penalties, the decision is no longer based solely on the merchant’s documentation, compliance, or actual products. It becomes a calculation of whether the processor can afford the risk.
That should concern every American business owner.
Lilly owns patents associated with tirzepatide. It does not own the entire peptide industry. Nevertheless, Visa’s enforcement approach appears to cast a much wider net, potentially affecting research suppliers and merchants offering compounds unrelated to Lilly’s patented medication.
Although Lilly has aggressively pursued peptide-related businesses, the complete extent of any direct communications between Lilly and Visa has not been publicly disclosed. That lack of transparency makes it even more important for Visa to explain exactly what conduct is triggering these fines.
Visa should disclose:
Which specific compounds are prohibited
Which laws, patents, or network rules justify the penalties
Whether all peptide merchants are affected or only sellers of tirzepatide
What evidence is required before a processor is fined
Whether merchants and processors have a meaningful appeal process
How legitimate research suppliers can demonstrate compliance
A private payment network should not use sweeping financial penalties to decide complicated questions of patent law, pharmaceutical regulation, and lawful commerce behind closed doors.
Allegations Should Not Be Treated as Court Judgments
If Lilly believes a particular company has violated one of its patents, it should identify the product, establish the alleged infringement, and pursue the matter through the proper legal process.
An allegation from a powerful corporation is not the same thing as a court judgment.
When a pharmaceutical company submits a complaint alleging patent infringement, trademark misuse, counterfeit products, or unlawful drug sales, Visa and the acquiring institution should investigate the facts. They should not automatically punish every company operating in a vaguely related industry.
Processors should be given:
The specific product alleged to infringe
The applicable patent number
Evidence connecting the merchant’s product to that patent
The exact advertising or representation being challenged
The applicable FDA, pharmacy, or network rule
A reasonable opportunity for the merchant to respond
A clear distinction between an accusation and an established violation
Visa’s fines encourage processors to terminate first and investigate later. That may protect Visa from liability and protect Lilly from competition, but it leaves legitimate businesses without clear rules, due process, or dependable access to the financial system.
“Research Use Only” Is Not an Automatic Defense
Peptide businesses must also accept responsibility for operating honestly and transparently.
Placing “research use only” on a website will not protect a business if its advertising clearly encourages human consumption. Dosage instructions, injection guides, medical promises, transformation photographs, human-use testimonials, bundled syringes, or disease-treatment claims can contradict the research-only designation.
Payment processors must conduct genuine underwriting and distinguish between:
Legitimate research suppliers
Licensed pharmacies
Properly operated medical and telehealth businesses
Merchants making misleading medical claims
Counterfeit or unlawful pharmaceutical sellers
Treating all these groups identically is not responsible risk management. It is indiscriminate financial deplatforming.
The appropriate answer is thorough underwriting, complete documentation, transparent marketing, laboratory verification, and ongoing compliance monitoring—not a blanket ban on an entire industry.
Protecting Patients—or Protecting Profits?
Lilly presents its campaign as an effort to protect patients. Safety is important, and no responsible company should defend contaminated drugs, counterfeit products, or deceptive medical claims.
But Lilly also earns billions of dollars from its GLP-1 medications. Restricting lower-cost alternatives and eliminating competition plainly benefits the company financially.
That does not prove every safety warning is insincere. It does mean regulators, banks, processors, and the public should examine Lilly’s claims critically rather than treating corporate statements as neutral public-service announcements.
When patent complaints are combined with card-network fines, the result gives an extraordinarily powerful corporation an advantage that extends well beyond the courtroom.
Patent protection was designed to reward innovation for a limited period. It was not intended to give a corporation unchecked authority to shut businesses out of the financial system without first proving that those businesses violated the law.
This Goes Beyond the Peptide Industry
Every American business owner should pay attention to what is happening.
If a corporation can use patent allegations and regulatory pressure to influence whether an entire category of businesses may accept credit cards, the same approach can eventually be used against other lawful but politically, culturally, or commercially disfavored industries.
Today, the target may be peptide companies. Tomorrow, it could be another industry that powerful institutions decide is too controversial or inconvenient to serve.
Visa and Mastercard operate essential payment infrastructure. Their decisions can determine whether a business survives. That power must be exercised transparently, consistently, and with respect for due process.
Private financial institutions should not be permitted to create punishments that effectively decide complex legal disputes before those disputes ever reach a courtroom.
2nd Amendment Processing Supports Fair, Evidence-Based Underwriting
At 2nd Amendment Processing, we believe lawful American businesses deserve honest underwriting, clear standards, and a meaningful opportunity to demonstrate compliance.
We do not support counterfeit drugs, misleading health claims, contaminated products, or illegal pharmaceutical sales. We also do not support powerful corporations using their influence to broadly restrict lawful competition or pressure financial institutions into treating unproven allegations as established violations.
Every peptide merchant must be evaluated individually. The merchant’s products, marketing language, fulfillment model, licensing, laboratory documentation, customer base, refund policy, and intended use should all be carefully reviewed.
One company’s tirzepatide patents should not become a blanket financial ban against the entire peptide industry.
Visa should publish clear rules, identify the specific products that create violations, establish a meaningful review process, and stop forcing processors to make complicated legal determinations under the threat of financial penalties.
Lilly is entitled to protect its legitimate intellectual property.
It is not entitled to own the peptide industry.
When patent protection is transformed into market control—and payment networks are used to enforce that control—it stops looking like responsible risk management.
It starts looking like corporate overreach.
This article is provided for general informational purposes and does not constitute legal, regulatory, medical, payment-network, or patent advice. Businesses should consult qualified professionals regarding their specific products, marketing practices, and operations.
Comments